Summary Carcinoma of the oesophagus is endemic in certain well demarcated areas throughout the world, and a method of screening population groups at high risk for oesophageal cancer is urgently needed. In this study the sensitivity and specificity of the carbohydrate antigen CA19-9 as a marker of carcinoma of the oesophagus in African patients was examined. The normal range was established by assay of serum samples from healthy black blood donors, using a solid phase radioimmunoassay with mouse monoclonal antibody to CAl9-9 labelled with 125I. Serum concentrations of CA19-9 were then measured in 100 African patients with oesophageal cancer and 28 patients with benign oesophageal disease. The upper limit of CA19-9 in the normal controls was 40 U ml-1. Thirty-four patients with oesophageal cancer and five with benign oesophageal disease had elevated levels. Therefore, in this series, the sensitivity of CA19-9 as a marker of oesophageal cancer was 34% and the specificity was 82%. While CA19-9 is not sufficiently sensitive to be used as a screening test of oesophageal cancer, it compares favourably with other known tumour markers of this disease, and may have a role in monitoring disease recurrence and response to treatment.
Carcinoma of the oesophagus is the commonest cancer in South Africa (McGlashen, 1988 (Kneebone & Mannell, 1985) . A simple method of screening this group is urgently needed: only by detecting oesophageal cancer in its early asymptomatic stage can these patients be cured of the disease.
Circulating tumour associated antigens, products of neoplastic cells which are secreted in excessive quantities into the blood stream, offer great potential in the early detection of cancer. When a specific marker of oesophageal carcinoma is identified, a simple blood test could be used to screen patients at risk for the development of this malignancy.
Carbohydrate antigen (CA19-9) is the specific carbohydrate fraction of a circulating antigen found in the serum of normal adults (Koprowski et al., 1981) . Excessive quantities of this antigen have been found in patients with gastrointestinal malignancies, including colorectal, pancreatic and hepatocellular carcinomas (Ritts et al., 1984; Kew et al., 1987) . The oesophagus, like the pancreas and liver, is a foregut derivative and it is possible that oesophageal carcinoma may also express this antigen.
The aim of this study was to measure serum concentrations of CA19-9 in black patients with oesophageal cancer and in those with benign oesophageal disease. The normal range was established by assays of serum samples from apparently healthy, age and sex-matched black subjects. The sensitivity and specificity of CA19-9 as a marker of squamous carcinoma of the oesophagus was then examined. Methods Blood samples, obtained by peripheral venipuncture, were centrifuged and the separated serum stored at -20°C, within 2h of collection. The serum samples were assayed for CA19-9 using a solid phase radioimmunoassay (Centocor CA19-9 Tm RIA system, Centocor Inc.) based on the 'forward sandwich' principle and utilising mouse monoclonal antibody to CA19-9 labelled with 125I.
Analysis of data CA19-9 levels greater than the upper limit in the normal controls were considered elevated and levels below the upper limit of normal as non-elevated. CA19-9 levels were reported to the nearest one-tenth Uml-1. The Welch one-way analysis of variance was the test employed to identify differences between the patient groups and the controls. After logarithmic transformation of the data, the pairwise t test was used to re-examine these differences. Sensitivity was defined as the number of patients with cancer of the oesophagus with an elevated assay level divided by the total number of patients with cancer of the oesophagus. Specificity was defined as the number of patients with benign oesophageal disease with non-elevated levels divided by the total number of patients with benign oesophageal disease. The positive predictive value of the test is the ratio of the number of cancer patients with an elevated assay level to the total number of patients with elevated levels. The negative predictive value of the test is the ratio of the number of non-cancer patients with a nonelevated assay level to the total number of patients with nonelevated levels.
Results
The distribution of CA 19-9 levels for the healthy controls, patients with oesophageal cancer and patients with benign oesophageal disease is summarised in Table I. The upper limit of CA19-9 in the normal controls was 40 U ml-1. Thirty-four patients with oesophageal cancer and five patients with benign oesophageal disease had elevated levels. The sensitivity of CA 19-9 as a test for oesophageal cancer was therefore 34% and the specificity was 82%. The positive predictive value of the test was 87% and the negative predictive value was 26%.
Statistical analysis
The CA19-9 levels in the two patient groups were significantly different from those of the normal controls (Welch test, P=0.001). However, after pairwise comparison of the mean CA19-9 levels, before and after logarithmic transformation of the data, no significant difference was identified between patients with oesophageal cancer and those with benign oesophageal disease.
Discussion
Monoclonal antibodies are beginning to acquire important practical implications in current medicine practice and monoclonal antibodies to cancer antigens offer great potential in the early detection of malignant disease activity as well as response to therapy (Torosian, 1988; Vugrin et al., 1984) . The populations at risk for the development of squamous carcinoma of the oesophagus have been clearly identified in such countries as South Africa, China, Iran and France (Kneebone & Mannell, 1985; Isaacson et al., 1978; Yang, 1980; Mufioz et al., 1982; Faivre et al., 1981) . But there is very little published data on the use of monoclonal antibodies to detect tumour associated antigens in the serum of patients with oesophageal cancer in these endemic areas.
Early studies of the oncofetal antigens, including carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) have proved disappointing. Serum CEA levels greater than lOngml-l were detected in 10% (Wahren et al., 1979) and 31% (Alexander et al., 1978) of patients with untreated oesophageal cancer in earlier studies. A later series of 162 cases with proven squamous oesophageal cancer showed that only 5% of patients had an elevated CEA level at the time of diagnosis (Melissas et al., 1983) .
AFP has proved even more disappointing. Using a cut-off point of 15ngml-1, Wahren et al. (1979) noted elevated AFP levels in 3.6% of patients with squamous carcinoma. No patient with oesophageal cancer in the small number reported by McIntire et al. (1975) at the Mayo Clinic had elevated AFP levels. However, recent work using monoclonal antibodies to detect squamous cell carcinoma antigen (SCCA) in patients with oesophageal cancer is more encouraging. Elias (1988) reported that this serological marker, first described in patients with squamous carcinoma of the cervix (Kato & Torigoe, 1977) , was elevated in 23.5% of patients with carcinoma of the oesophagus.
Although the CA19-9 assay was originally developed to detect patients with colorectal adenocarcinoma (Koprowski et al., 1981) , subsequent work revealed that the serum levels of this antigen were raised in a greater proportion of patients with pancreatic and hepatobiliary malignancies than those with large bowel cancer (Ritts et al., 1984; Kew et al., 1987) . The oesophagus, like the pancreas and the liver, is a foregut derivative and this study was undertaken in the hope that CA19-9 might prove a useful tumour marker for oesophageal carcinoma.
The evaluation of a tumour marker necessitates investigation of benign conditions which could be considered in the differential diagnosis of the tumour for the presence of the marker. Benign tumours of the oesophagus are rare (Gowing, 1961) . Therefore, patients with oesophagitis, the most common benign condition of the oesophagus which can also present with dysphagia, were investigated for the presence of CA19-9 in the serum. Ritts et al. (1984) , in a series of eight patients with oesophageal cancer, noted one patient (13%) to have a CA19-9 level of >40Uml-1. Our series has shown that elevated levels of CA19-9 are present in 34% of patients with oesophageal cancer at the time of diagnosis. These results compare very favourably with similar studies of other tumour markers in carcinoma of the oesophagus. But it is evident that CA19-9 is not sufficiently sensitive or specific for use as a screening test of population at risk for this malignancy. The reason why five of the 28 patients with oesophagitis also had elevated levels of CA19-9 is uncertain. One possible explanation lies in the fact that monoclonal antibodies to CA19-9 react with a high molecular weight mucin antigen as well as a low molecular weight ganglioside (Steinberg et al., 1986) and that inflammation of the oesophagus may lead to an increased production of mucin by the oesophageal mucus-secreting glands. Antigens derived from the oesophageal mucus if present in the circulation, could then be recognised by the anti CA19-9 monoclonal antibodies.
Another explanation possible is that oesophagitis in black patients could be a pre-malignant condition (E. Dowdle, personal communication, 1988) . Support for this hypothesis would require mass screening of the African population at risk by both CA19-9 assay and endoscopic examination of the oesophagus, a study which is not feasible at this time.
Although CA19-9 does not fulfil the requirements of an ideal serological tumour marker (Torosian, 1988) for oesophageal cancer, it may have value in monitoring disease recurrence or response to therapy, similar to the role of CEA in the follow-up of patients treated for colorectal tumours (Mayer et al., 1978; Mach et al., 1974) . For this reason serial assays of CA19-9 are currently being performed in those patients in this study who have been treated for oesophageal cancer, and will be the subject of a later report.
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